Last reviewed · How we verify
MA-0211
At a glance
| Generic name | MA-0211 |
|---|---|
| Also known as | ASP0367 |
| Sponsor | Astellas Pharma Global Development, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy (PHASE2)
- A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction (PHASE1)
- A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD) (PHASE1)
- A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men (PHASE1)
- A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People (PHASE1)
- A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function (PHASE1)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MA-0211 CI brief — competitive landscape report
- MA-0211 updates RSS · CI watch RSS
- Astellas Pharma Global Development, Inc. portfolio CI